Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARC-520 plus entecavir or tenofovir in HBeAg-positive chronic hepatitis B (Germany, Phase 2)
2014-004751-31Phase 2Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Mar 2015
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ARC-520 in Chronic Hepatitis B (CHB) (4 arms), sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Change in quantitative HBsAg at Day 113. Started Mar 2015; status: completed.
02
Drugs
ARC-520
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2014-004751-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004751-31.